45 results about "Insulinlike growth factor" patented technology

The present invention provides compositions and methods of use of anti-IGF-1R antibodies or antibody fragments. Preferably the antibodies bind to IGF-1R but not IR; are not agonists for IGF-1R; do not block binding of IGF-1 or IGF-2 to isolated IGF-1R, but effectively neutralize activation of IGF-1R by IGF-1 in intact cells; and block binding of an R1 antibody to IGF-1R. The antibodies may be murine, chimeric, humanized or human R1 antibodies comprising the heavy chain CDR sequences DYYMY (SEQ ID NO:1), YITNYGGSTYYPDTVKG (SEQ ID NO:2) and QSNYDYDGWFAY (SEQ ID NO:3) and the light chain CDR sequences KASQEVGTAVA (SEQ ID NO:4), WASTRHT (SEQ ID NO:5) and QQYSNYPLT (SEQ ID NO:6). Preferably the antibodies bind to an epitope of IGF-1R comprising the first half of the cysteine-rich domain of IGF-1R (residues 151-222). The anti-IGF-1R antibodies may be used for diagnosis or therapy of various diseases such as cancer.

The present invention relates to methods and compositions for monitoring, diagnosis, prognosis, and determination of treatment regimens in subjects suffering from or suspected of having a renal injury. In particular, the invention relates to using a plurality of assays, one or more of which is configured to detect a kidney injury marker selected from the group consisting of Hyaluronic acid, Immunoglobulin A, Immunoglobulin G1, Immunoglobulin G2, Insulin-like growth factor-binding protein 7, Alpha-1 antitrypsin, Serum amyloid P component, Metalloproteinase inhibitor 2, Hepatocyte growth factor, Intercellular adhesion molecule 1, Beta-2-glycoprotein 1, Interleukin-1 beta, Neutrophil Elastase, Tumor necrosis factor receptor superfamily member 11B, Interleukin-11, Cathepsin D, C—C motif chemokine 24, C—X—C motif chemokine 6, C—C motif chemokine 13, C—X—C motif chemokines -1, -2, and -3, Matrilysin, Interleukin-2 receptor alpha chain, Insulin-like growth factor-binding protein 3, and Macrophage colony-stimulating factor 1 as diagnostic and prognostic biomarkers in renal injuries.

The invention relates to a degradable wound repair material and a preparation method thereof. The degradable wound repair material includes a matrix component and an auxiliary component, wherein the matrix component includes a protein ingredient, and the auxiliary component includes at least one of an antibacterial agent and an active factor. Specifically, the antibacterial agent is a synthetic antibacterial drug, an inorganic antibacterial agent, an organic antibacterial agent, or a natural antibacterial agent, and the active factor is at least one of the following active factors: an epidermal growth factor, an FGF vascular endothelial growth factor, a platelet-derived growth factor, a platelet activating factor, an insulin-like growth factor, a tumor necrosis factor, interleukin, colony stimulating factor-1, various bone morphogenetic proteins or transforming growth factors. By loading the antibacterial agent and active factor component on the basis of the matrix component, the degradable wound repair material provided by the invention can have biological activity on the basis of meeting degradability, can better promote wound repair, and has good anti-infection properties during use.

A method of inhibiting cellular activation by Insulin-like Growth Factor-1 (IGF-1) in a subject in need thereof (e.g., a subject afflicted with cancer, atherosclerosis, diabetic retinopathy or other disease) comprises administering an antagonist that inhibits the binding of IAP to SHPS-1 to the subject in an amount effective to inhibit cellular activation by IGF-1. Compounds and compositions for carrying out such methods are also described.

Peptides are provided that inhibit the interaction of an IGF with any one of its binding proteins and not to a human IGF receptor. These IGF agonist peptides are useful to increase serum and tissue levels of active IGFs in a mammal.

Compositions and methods are provided for treatment growth hormone and/or insulin-like growth factor 1 deficiency in a patient in need of such treatment. Compositions and methods include novel vaccines that provide immunogenicity for somatostatin and result in the increased release of endogenously produced growth hormone and/or insulin-like growth factor 1.

Method for the production of IGF-I, characterized by cultivating a prokaryotic host cell comprising an expression vector containing a nucleic acid encoding a fusion protein comprising said IGF-I N-terminally linked to the C-terminus of a propeptide, whereby said propeptide ends C-terminally with amino acids -Y-Pro, wherein Y is selected from the group consisting of Pro, Pro-Ala, Pro-Gly, Pro-Thr, Ala-Pro, Gly-Pro, Thr-Pro, Arg-Pro, or Pro-Arg-Pro, recovering and cleaving said fusion protein with IgA protease, and recovering said IGF-I. IGF-I is useful for the treatment of neurodegenerative disorders like Alzheimer's Disease.

The invention relates to a follicular cell activator composition and preparation and their application. A follicular cell activator comprises at least two of a bFGF (basic fibroblast growth factor), an KGF or KGF1 (keratinocyte growth factor or keratinocyte growth factor 1), a KGF2 (keratinocyte growth factor 2), an IGF-1 (insulin-like growth factor 1), a VEGF (vascular endothelial growth factor),an HGF or HGF alpha (hepatocyte growth factor or hepatocyte growth factor alpha), an FGF18 (fibroblast growth factor 18), an SCF (stem cell factor), an FGF20 (fibroblast growth factor 20), an NGF (never growth factor), a GH (growth hormone) and Wnt3a protein. The follicular cell activator preparation herein can regulate proliferation, differentiation, regeneration and metabolism of follicular cells, and improve microcirculation to restore follicles and effectively treat seborrheic alopecia and other types of hair loss.

The invention discloses a method for preparing recombined human insulin growth factor-1(IGF-1) fused protein, which belongs to the field of biological medicine field in biological technique. The invention adopts the genetic engineering fungus fermentation method for production: a. designing and synthesizing recombining human IGF-1 fused protein gene; b. constructing an expression vector of the recombined human IGF-1 fused protein; c. utilizing the expression vector to convert the host to construct the genetic engineering fungus; and d. utilizing the genetic engineering fungus to ferment the recombined human IGF-1 fused protein. In the method, according to the characteristics that the first amino acid of the natural IGF-1 is glycine(GLy, G), a leading peptide is added before the natural IGF-1, and a hydroxylamine specific cracking part(Asn-Gly peptide bond) is designed between the leading peptide and the natural IGF-1, thereby making the expression products stable and lowering purification cost. In the method, the fused protein in serial expression is used, wherein the N end is thioredoxin, and the C end is IGF-1, so that the expression products are more stable, and the separation method is simple and cheap. The method has wide application prospect.

The present invention provides αVβ3 integrin cysteine loop domain agonists and antagonists (including peptide agonists and antagonists and analogs thereof), along with methods of using the same.

An isolated protein complex is provided which includes a growth factor, growth factor binding protein and vitronectin. Preferably, the isolated protein complex includes an insulin-like growth factor-I, insulin-like growth factor binding protein-3 or insulin-like growth factor binding protein-5 and vitronectin. Also provided are methods of modulating cell proliferation and/or migration by administering said protein complex for the purposes of wound healing, skin repair and tissue replacement therapy. Conversely, by using agents that disrupt growth factor protein complexes formed in vivo, growth factor-driven cell proliferation and/or migration may be suppressed such as for the purposes of treating cancers, psoriasis, atherosclerosis and wounds prone to hypertrophic scarring.

The invention relates to a non-serum non-animal origin protein animal cell culture used fetus cattle serum displace agent, which is formed by recombination human insulin growth factor-1:0.1g-0.5g/l, recombination human platelet sourced growth factor-B:0.1g-0.6g/l, recombination human alkali desmocyte growth factor: 0.05-0.4g/l, polyethylene glycol (MW7000-20000), 0.04-0.15%(w/v), polyvinyl alcohol (density 1.27-1.31): 0.001-0.05%(w/v), mercaptoethanol: 0.3-0.5mol/l.

The invention provides a method for detecting a special growth and development law of muscles of Jingning chicken. The Jingning chicken are unique and peculiar local chicken of the Gansu province, are fresh and tender in texture and unique in flavor, and have good public praise, however, the Jingning chicken are endangered, and the prospect is grim. In the method for detecting the special growth and development law of the muscles of the Jingning chicken, chick embryos of the Jingning chicken are researched, and special meat quality trait controlling genes such as growth and development gap-associated proteins: CECR2 (cat eye syndrome chromosome region) and IGF-1 (insulinlike growth factor-1), fatty acid metabolism gap-associated proteins: Ex-FABP (fatty acid-binding protein) and LPL (lipoprotein lipase) and protein degradation gap-associated proteins: CAST and CAPN1 are selected. Protein expression distribution and change of expression level of proteins in posterior limb buds and body segments in a chick embryo development HH19-31 period are detected by using methods of immunohistochemistry and Western blotting and the like, and the Jingning chicken are compared to white feather broilers, yellow feather broilers and hyline brown chicken. By the method for detecting the special growth and development law of the muscles of the Jingning chicken, the relation of growth and development regulatory functional genes, growth performance and meat quality is discussed, and data are provided for establishing target genes of transgenic chicken. Moreover, the resource superiority can be widely developed and used, and new vitality is injected to development of local economy.

The present invention relates to a peptide having the activity of insulin like growth factor-1 (IGF-1) and derived from IGF-1, a composition for improving skin conditions or treating a periodontal disease comprising the peptide. The IGF-1 mimicking peptides of this invention have identical functions or actions to natural-occurring IGF-1 and much better stability and skin permeation than natural-occurring IGF-1. In these connections, the composition comprising the peptides of this invention can exhibit excellent efficacies on the treatment, prevention and improvement of diseases or conditions demanding IGF-1 activities. In addition, the peptides of this invention can be advantageously applied to pharmaceutical compositions, quasi-drugs and cosmetics.

The invention provides an encoding gene of a recombinant insulin-like growth factor, lactobacillus containing the encoding gene and application of the lactobacillus, and belongs to the field of bio-genetic engineering. The insulin-like growth factor is a multifunctional cell proliferation regulation factor, has important acceleration in differentiation, proliferation, and growth and development of cells, but has the problems of insufficient throughout, high price, required purification of product, difficult drug administration and the like just as most of genetic engineering drugs. In order to obtain a lot of recombinant insulin-like growth factors, recombinant insulin-like growth factor genes optimized by codons are subjected to heterologous expression by adopting a lactobacillus expression system, and the recombinant lactobacillus is utilized as a living bacteria agent or a feed additive to enhance the nonspecific immunity of a pig.

The invention relates to a composition for inducing mature neuron division and a purpose thereof, in particular to the composition for inducing the mature neuron division. The composition contains EGFs (Epidermal Growth Factors), bFGFs (basic Fibroblast Growth Factors), HGFs (Hepatocyte Growth Factors), IGFs (Insulin-Like Growth Factors), NGFs (Nerve Growth Factors), BDNFs (Brain-Derived Neurotrophic Factors) and T3 (tri-iodothyronine).

The invention relates to a chicken sternal cartilage powder and a preparation method and application thereof. In the chicken sternal cartilage powder, the content of glucosamine is 10-15g/100g, the content of chondroitin sulfate is 1-2mg/100g, the content of hydroxyproline is 4-8g/100g, the content of basic fibroblast growth factor is 0.5-2.5mug/100g, and the content of insulin-like growth factor-1 is 0.1-0.5mg/100g; the preparation method comprises the following steps: taking fresh chicken sternal cartilage, completely removing non-cartilage matter, cleaning up and cutting into thin slices; freezing for at least 12-24 hours under the conditions below 60 DEG C, and freeze-drying; and then carrying out ultrafine grinding at a low temperature to obtain the chicken sternal cartilage powder. The preparation method of the chicken sternal cartilage powder provided by the invention is easy, convenient and feasible in technical scheme, strong in standardization, low in energy consumption, cost-saving and high in yield, and preserves the nutritional value of the chicken sternal cartilage to a greater extent.

The invention relates to a composition containing rhizoma atractylodis macrocephalae and application thereof. The composition contains the following raw materials, or extracts of the following raw materials, or derivatives of the extracts of the following raw materials in chemically-acceptable forms, wherein the raw materials include processed products prepared from the raw materials. The composition comprises the following raw materials in parts by weight: 100 parts of rhizoma atractylodis macrocephalae; and according to specific circumstances, one or more selected from (but not limited to) the following raw materials can be added on this basis: 50-150 parts of radix astragali, 50-150 parts of Chinese yam, 50-150 parts of radix pseudostellariae, 50-150 parts of radix paeoniae alba, 50-150 parts of schisandra fruit, 50-150 parts of tuckahoe and 50-150 parts of licorice root. The composition provided by the invention can be prepared into powder, liquid, paste, granules, capsules or other pharmaceutically-acceptable physical forms. The composition provided by the invention is used for promoting the expression of insulin-like growth factors, promoting the division and membrane fusion of myoblasts, accelerating the growth and development of muscle fibers and increasing the number of karyons, thereby realizing the quick growth of muscle tissues.